Merck annual report 2012. Merck 2019-02-20

Merck annual report 2012 Rating: 6,8/10 1609 reviews

Merck & Co., Inc. Annual Report on Form 10

merck annual report 2012

This may lead to individual values not adding up to the totals presented. In addition, ¬≠Bavencio ¬ģ was approved for the treatment of patients with urothelial carcinoma in Israel in late January 2018. For more information, visit and connect with us on Twitter, Facebook and YouTube. Includes expenses for the amortization of intangible assets and amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as intangible asset impairment charges. Both new technologies are being intensively tested by customers ‚ÄĒ initial quantities to manufacture the corresponding ¬≠display panels have already been sold.


Next

Merck & Co., Inc.

merck annual report 2012

With these pigments from the Iriotec ¬ģ 8000 series, circuit layouts can be integrated into injection-molded components or powder-coated components in laser direct structuring processes. We also help to raise awareness and education in the areas we operate in, such as thyroid diseases and diabetes. We need curiosity in order to understand technical progress and to shape our future actively and responsibly. The Process Solutions business unit delivers end-to-end products and expertise to customers who take what is developed in labs and manufacture it. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. Employees must demonstrate a commitment to Client focus, People focus, Trust and Teamwork focus, Excellence focus and Respect and Integrity focus. The ¬≠acquisition complements our efforts to drive next-generation bio¬≠processing, ultimately enabling faster and more efficient technology for customers.

Next

Merck

merck annual report 2012

Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. The center houses two laboratories developing applications for coating materials and semiconductor packaging in order to provide future-oriented support to our customers. In 2017, we continued to optimize our web channel and streamline the customer experience, resulting in increased user sessions and revenue. These figures refer to all people directly employed by Merck and therefore may deviate from figures in the financial section of this report. Single-use technology is becoming increasingly popular in the industry. We're seeing significant progress in the pipeline this year, and we expect six major filings over the next 18 months, including suvorexant for insomnia and odanacatib for osteoporosis. We are the only company to offer recombinant versions of the three natural hormones needed to treat infertility as well as a ­complete and clinically tested portfolio for every stage of the reproductive cycle.

Next

Merck & Co., Inc.

merck annual report 2012

With our three business sectors Healthcare, Life Science and Performance Materials, we are not only successful, but also improve the lives of patients, customers and partners all over the world. For example, the Life Science business sector created the first-ever commercially available cell line platform for faster, simpler selection and scale-up of high-­producing clones for making recombinant protein drugs. It belongs to the improved product generation of the well-known high-tech effect pigments and stands out due to an attractive bluish red and very intense glitter. After successfully orchestrating the largest integration in the history of Merck, the Life Science business sector redesigned its organizational structure in the second quarter of 2017 to capture growth opportunities even more nimbly and to align the entire organization to optimally contribute to, and capitalize on the strength of the Merck Group. This is critical to customers ranging from contract manufacturing organizations to large pharma companies, whose biggest challenge is getting custom assembly with fast, reliable lead times for quicker turnarounds and more rapid biomanufacturing. This is an important milestone for capturing a new market segment for liquid crystals. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Next

Merck

merck annual report 2012

The acquisition strengthens our ­ability to help customers protect the global food supply by providing an extensive portfolio of state-of-the-art testing technology. Occupancy Planning and Move Management The Merck account Occupancy Planning team achieved a Bronze Supernova certification in 2013 and is in the final review for receiving another Supernova award based on their accomplishments in 2014. For its innovative 3D effect printing technology, Merck entered into a strategic partnership with Schmid Rhyner of Switzerland. The Summer Development Series officially ended in early September. In Healthcare, we discover, develop and manufacture prescription medicines used to treat cancer, multiple sclerosis, and infertility. A replay of the call will be available starting at 11 a.

Next

Merck & Co., Inc. Annual Report on Form 10

merck annual report 2012

Its competitive differentiation is based on its favorable ecotoxicological profile, and even in very low concentrations it significantly improves the flow and wetting behavior of coating systems. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Concor ¬ģ, containing bisoprolol, is the leading beta-blocker for chronic cardiovascular diseases such as hypertension, coronary artery disease and chronic heart failure. Approvals followed in Australia and Israel in early 2018. The Life Science Research Solutions business unit serves customers focused on identifying and developing new medicines.

Next

Merck & Co., Inc. Annual Report on Form 10

merck annual report 2012

We use our documented successes to improve in other areas, ensuring we consistently deliver the highest levels of customer service and consistent service delivery. We provide trusted products and comprehensive workflow solutions that streamline processes, lower costs and deliver consistent, reliable results. The ­prognosis for both patient groups is very poor, so for patients around the world this may represent a welcome new treatment option. In recent years, we have steadily expanded our presence in growth markets. The company assumes no duty to update the information to reflect subsequent developments.


Next

Merck

merck annual report 2012

With a market share above 40% and double-digit sales growth, Euthyrox ¬ģ active ingredient levothyroxine is the worldwide market leader for treating hypothyroidism, a disease with high prevalence but low diagnosis in most emerging markets. The new center gives customers access to a ¬≠complete food-safety workflow, from raw materials testing to ¬≠finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. In the field of organic photovoltaics, more and more pilot projects demonstrate the manifold applications of the technology in architecture. We hold the global rights to the Merck name and brand. It is the first application laboratory for pigments and functional materials in China, through which we offer our customers comprehensive tailored services for our products and at the same time work with them to develop new products. The aim is to further develop this innovative printing process with effect pigments for various surfaces and markets.

Next

General

merck annual report 2012

Our products help millions of people around the world. In accordance with the provisions of the German financial reporting disclosure law Publizit√§tsgesetz , consolidated financial statements are also prepared for E. We are therefore focusing on turning these trends into opportunities for Merck to achieve further growth. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. Strategic realignment In 2018, we want to focus even more strongly on the needs of our customers and markets. We serve customers in academia, biotech and pharma ‚ÄĒ helping them to deliver the promise of their work better, faster and safer.

Next

Merck Co., Inc. (MRK) 10K Annual Reports & 10Q SEC Filings

merck annual report 2012

Personalized medicine has been a reality for ¬≠Allergopharma for many years now. Milli-Q ¬ģ water has become synonymous with ultrapure lab water and is the most cited brand in peer-reviewed publications. In Display Materials, our ¬≠largest business unit, we observed a normalization of our market shares in the liquid crystals sector in 2017. This may lead to individual values not adding up to the totals presented. The capacities at the application laboratory in Korea were doubled in 2017. We need curiosity in order to understand technical progress and to shape our future actively and responsibly. The decrease was primarily due to ongoing productivity measures.

Next